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In vitro AND in vivo ANTILEISHMANIAL EFFICACY OF A COMBINATION THERAPY OF 
DIMINAZENE AND ARTESUNATE AGAINST Leishmania donovani IN BALB/C MICE
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SUMMARY
The in vitro and in vivo activity of diminazene (Dim), artesunate (Art) and combination of Dim and Art (Dim-Art) against 
Leishmania donovani was compared to reference drug; amphotericin B. IC50 of Dim-Art was found to be 2.28 ± 0.24 µg/mL while 
those of Dim and Art were 9.16 ± 0.3 µg/mL and 4.64 ± 0.48 µg/mL respectively. The IC50 for Amphot B was 0.16 ± 0.32 µg/mL 
against stationary-phase promastigotes. In vivo evaluation in the L. donovani BALB/c mice model indicated that treatments with the 
combined drug therapy at doses of 12.5 mg/kg for 28 consecutive days significantly (p < 0.001) reduced parasite burden in the spleen 
as compared to the single drug treatments given at the same dosages. Although parasite burden was slightly lower (p < 0.05) in the 
Amphot B group than in the Dim-Art treatment group, the present study demonstrates the positive advantage and the potential use 
of the combined therapy of Dim-Art over the constituent drugs, Dim or Art when used alone. Further evaluation is recommended to 
determine the most efficacious combination ratio of the two compounds.
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INTRODUCTION
Visceral leishmaniasis (VL), also known as Kala azar, is a protozoan 
systemic infection which is always fatal if left untreated. This illness was 
included by the World Health Organization in the list of neglected tropical 
diseases targeted for elimination by 2015 (MALTEZOU, 2010). The first 
line chemotherapeutic agents, such as pentavalent antimonial compounds: 
pentostam and glucantime (CROFT & COOMBS, 2003), remain the 
drugs of choice for all forms of leishmaniasis in spite of their reported 
toxicity. Amphotericin B (Amphot B) and pentamidine, the second line 
drugs, remain of limited value because of toxicity (BERMAN et al., 
1998) and prohibitively high cost (WHO, 2007). Miltefosine, initially 
developed as an anticancer drug, is the first effective oral treatment of 
visceral leishmaniasis (VL) and the latest antileishmanial drug to enter 
the market (Croft and Coombs, 2003). Drug resistance in leishmaniasis 
has been reported in all these drugs (MAAROUF et al., 1998; CROFT 
et al., 2006). Even before miltefosine is introduced into the market or 
into control programs, preliminary data from a phase IV trial in India 
involving domiciliary treatment with miltefosine and weekly supervision 
suggests doubling of the relapse rate (SUNDAR & MURRAY, 2005); 
this provides warning that drug resistance could develop quickly and 
plans are required to prevent it.
Combination therapy of antileishmanial drugs is currently considered 
as one of the most rational approaches to lower treatment failure rate 
and limit the spreading of drug resistance (GUERIN et al., 2002; 
GAZANION et al., 2011). Diminazene (Dim) has been tested and found 
to have trypanocidal and leishmanicidal activities on various strains of 
trypanosomes (Trypanosoma vivax, T. evansi and T. congolense) and on 
L. donovani in hamsters (CLEMENT et al., 1992). 
Studies conducted in the 1970s suggested the potential of berenil 
(diminazene diaceturate) as leishmanicidal agent (LEON et al., 1977). 
Trypan®: a diminazene drug was tested against both Leishmania major 
and L. donovani in vitro by MACHARIA et al. (2004) and the drug was 
found to be efficacious. The same experiment also carried out in vivo 
studies with Trypan® using BALB/c mice with cutaneous leishmaniasis 
after infection with L. major promastigotes. Results showed delayed 
lesion development depending on the route of drug administration. 
Dim granules represent a new formulation, containing, in part, Dim 
aceturate in addition to other new ingredients. Dim is formulated for 
both oral and parenteral (intramuscular and intravenous) administration. 
Artesunate (Art), dihydroartemisinin-10α- hemisuccinate, is a semi-
synthetic derivative of artemisinin which is used for the treatment of 
both uncomplicated and severe malaria (OLLIARO et al., 2001). It 
is formulated for oral, parenteral and rectal administration and used 
clinically worldwide. Because of rapid hydrolysis to dihydroartemisinin 
(also referred to as artenimol), Art is considered by many as a prodrug 
of the latter (NAVARATNAM et al., 2000). Dim and Art granules are 
relatively new products and their synergistic effect has not been tested 
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for its potential application against leishmaniasis. The present study 
investigated the protective potential of Dim combined with Art in BALB/c 
mice experimentally infected with L. donovani. The efficacy of the drug 
combination and the survivorship of the study subjects are discussed. 
MATERIALS AND METHODS
Parasites for infection: Leishmania donovani strain NLB-065 
originated from the spleen of an infected patient and is maintained 
by intracardiac hamster-to-hamster passage at the Institute of Primate 
Research. A hamster splenic aspirate was cultured in Schneider´s 
Drosophila insect medium supplemented with 20% fetal bovine serum 
and 100 µg/mL of gentamicin at 25 °C till stationary phase. Parasites 
harvested in stationary phase after 8-10 days of culture were centrifuged 
at 2500 rpm (Servoll 6000D) for 15 min at 4 °C and washed three times 
in sterile phosphate-buffered saline before being counted and used for 
inoculation in animals. 
Chemicals: Dim diaceturate and Art (dihydroartemisinin-10α- 
hemisuccinate) granules were provided by Dr Alain Bourdichon 
(TropMed, Germany). The compounds were weighed separately, mixed 
in a 1:1 ration by weight and used in dosages of 12.5 mg/kg of body 
weight. Art and Dim were also individually used at dosages of 12.5 mg/
kg. Amphot B at doses of 12.5 mg/kg was used as a positive control drug.
In vitro evaluation against Leishmania donovani promastigotes: 
Stationary-phase promastigotes harvested as described above were 
counted and suspended in a concentration of 2.0 x 106 parasites/mL in 
culture medium. With a few modifications, the tests were performed 
as previously described (OKPEKON et al., 2004). The tests were 
performed in 96-well microtitre plates maintained at 26 ºC under 5% 
CO2 atmosphere. Two hundred microliters of complete Schneider´s 
Drosophila medium was placed in the wells containing the maximum 
concentrations of the compounds and 100 µL in the next wells (2 to 12) 
and controls; 2 µL of compound solutions of 20 mg/mL in distilled water 
were added to wells number 1 and serial dilutions (ranging from 100 µg/
mL to 0.049 µg/mL) in the wells were performed. Hundred microliters 
of culture medium containing 2.0 x 106 stationary-phase Leishmania 
parasites/mL was added to each test well. Tests were performed two 
times each with three replications for each test compound concentration. 
Parasite observations and counting were done using a microscope. The 
results are expressed as the concentration inhibiting parasite growth by 
50% (IC50 ± SD) after 72 h incubation period. The initial concentrations 
for testing were 100 µg/mL.
In vivo evaluation against Leishmania donovani: Six to eight week-
old BALB/c mice of mixed sexes were infected with 1 x 106 virulent L. 
donovani strain NLB-065 harvested at stationary phase as previously 
described. Infected mice were kept for nine weeks for symptomatic 
establishment of VL. Infection was assessed in three mice by culture of 
splenic aspirate and impression smears. The animals were then divided 
into five groups of six mice each and treated with either Amphot B, Dim, 
Art, or Dim-Art. One group was not treated and it served as a control. 
All drugs were given at dosages of 12.5 mg/kg of body weight. All 
doses were administered consecutively for 28 days from week 10 post 
infection. During the treatment period, parasite load was determined in 
any animal that died. In week 14 post infection (day 97), all mice groups 
were sacrificed and parasite numbers determined microscopically by 
counting the number of amastigotes/500 splenic cell nuclei in Giemsa-
stained impression smears. Amastigote burden was compared for both 
treated and untreated mice groups.
Mice survival rate: During treatment period, weeks 10 to 14, all 
animal groups were observed at least every 12 hours and any death that 
occurred during this time was recorded.
Statistical analysis: All parasite burden data were expressed 
as the mean per 500 cell nuclei of spleen cells ± standard deviation. 
Differences among groups were analyzed by one-way analysis of 
variance (ANOVA), and the post hoc Tukey-Krammer test method was 
used for multiple comparisons. A p-value of p < 0.05 was considered 
statistically significant. All analyses were performed using the GraphPad 
InStat software.
RESULTS
The in vitro antileishmanial effects of Dim, Art, Dim-Art and 
reference drug Amphot B on the growth of L. donovani promastigotes are 
presented in Table 1. These results indicate that Dim-Art (IC50 of 2.28) 
was more than twice and more than four times effective in inhibiting 
promastigotes growth as compared to Art (IC50 of 4.64) and Dim (IC50 
of 9.16) respectively.
The in vivo antileishmanial effects of 12.5 mg/kg of each of Dim, Art 
and Dim-Art and reference drug, Amphot B are presented in Figure 1. 
These results indicate that, Dim/Art significantly reduced parasite loads 
when used in this combined form than when used as single drug therapy 
of Dim-Art (p < 0.001). 
The reference drug, Amphot B, indicated only a slight reduction of 
parasite load when compared to the Dim-Art (p < 0.05). There was no 
difference in antleishmanial activity by Dim and Art (p > 0.05). However, 
all drugs significantly reduced parasite loads as compared to the control 
group (p < 0.001).
The survival rates of mice during treatment are shown in Figure 2. 
No death was observed in any mouse from each of the Art, Dim-Art 
or the Amphot B groups throughout the experimental period and this 
concluded a highly significant survival rate in these groups as compared 
to the control group (p < 0.001). The rate of mice survival in the Dim 
group was not different from all the other treated mice groups (p > 0.05). 
This survival rate was however significantly higher in the Dim treated 
group than in the control mice group (p < 0.05). 
Table 1
IC50 values of Dim, Art, Dim-Art and reference drug Amphot B on L. donovani 
promastigotes
Compound IC50 (µg/mL)
Dim 9.16 ± 0.3
Art 4.64 ± 0.48
Dim-Art 2.28 ± 0.24
Amphot B 0.16 ± 0.32
Mean of IC50 (µg/mL) ± SD
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DISCUSSION
Drugs currently available for leishmaniasis treatment often show 
parasite resistance, high toxic side effects and prohibitive costs 
commonly incompatible with patients from the tropical endemic 
countries (SIQUEIRA-NETO et al., 2010). Combination therapy 
between commercially available drugs that are aimed to reduce cost, 
toxicity and duration of treatments, represents a promising rational 
alternative (GAZANION et al., 2011). In this study, we evaluated the 
possible application of Art, an antimalarial drug, in combination with 
Dim diaceturate as an antileishmanial drug therapy. Dim has been tested 
and found to have trypanocidal and leishmanicidal activities on various 
laboratory strains of trypanosomes (Trypanosoma vivax, T. evansi and 
T. congolense) and on L. major in mice (MACHARIA et al., 2004) and 
L. donovani in hamsters (CLEMENT et al., 1992). Dim diaceturate is 
a Dim currently undergoing trial for treatment of trypanosomiasis. Our 
present study shows the positive advantage of Dim-Art combination over 
the use of its constituent drug compounds in the treatment of visceral 
leishmaniasis. Dim-Art indicated an efficacy level of more than twice and 
more than four times in inhibiting parasites growth in culture as compared 
to Art and Dim respectively. This is an indication that the combined 
therapy is more potent than the single drugs with the presence of Art 
contributing more to the potency than the Dim compound. The lack of 
complete elimination of parasites by the Dim-Art combined therapy or 
the Amphot B may be attributed to delayed start of treatments of infected 
mice. Furthermore, treatment began when most of the mice had shown 
severe symptoms of the disease and it may be possible that these two 
drugs could only completely eliminate parasites when administered for 
a longer period in cases of advanced disease. 
In the current study, we monitored for animal survival during the 
experimental period. The survival of 100% of the populations treated with 
either, artesunate, Dim-Art or Amphot B up to the end of the experimental 
period may be attributed to significantly reduced parasite loads observed 
in these groups. This is an indication of a potential value of these drug 
compounds in the control of Leishmania parasite multiplication. Fifty 
percent of the total population treated with Dim and over 80% of mice 
in the control group died before termination of the experiment. It was 
observed that any animal that died from any of these two groups before 
the end of the experimental period had a parasite load of at least 130 
parasites per 500 nucleated spleen cells. BALB/c mice fail to control 
infection and they develop progressive lesions and systemic disease 
(SACKS & NOBEN-TRAUTH, 2002). This may point to inability of the 
Dim drug to control parasite growth and hence the death of some mice 
in this group. Following administration of any of the compounds used in 
this study, we did not observe any side effects attributable to the dosages 
of the regimen given. Furthermore, earlier experiments in our laboratory 
showed no side effects when Dim was administered in L. major-infected 
mice (MACHARIA et al., 2004). We did not observe any adverse effects 
of these chemicals when delivered into the mice nor did we observe any 
morphological changes in the parasites in the in vitro test system and 
this may give an indication that parasite death or the death of mice was 
not caused by drug toxicity.
In conclusion, we have demonstrated the positive advantage and 
possible application of Dim-Art drug combination in the safe and 
effective treatment of VL. It is possible that much of the efficacy of this 
drug combination is attributable to the presence of the Art compound and 
hence the need for further experimental design to establish the curative 
combination ratio and toxicity parameters of these compounds.
RESUMO
Estudo in vitro e in vivo da eficácia anti leishmaniótica de 
terapêutica combinada de Diminazene e Artesunate contra 
Leishmania donovani em camundongos Balb/c
A atividade in vitro e in vivo de Diminazene (Dim), Artezunate (Art) 
e a combinação Dim e Art (Dim-Art) contra Leishmania donovani foi 
comparada com a droga de referência Anfotericina B. IC50 da Dim-Art foi 
2,28 ± 0,24 µg/mL enquanto aquelas de Dim e Art foram 9,16 ± 0,3 µg/mL 
e 4,64 ± 0,48 µg/mL respectivamente. O IC50 da Anfotericina B foi 0,16 
± 0,32 µg/mL contra a fase estacionária de promastigotas. A avaliação in 
vivo do modelo de L. donovani em camundongos Balb/c indicou que os 
tratamentos com a terapêutica de drogas combinadas em doses de 12,5 
mg/kg por 28 dias consecutivos significantemente (p < 0,001) reduziu 
a carga parasitária no baço quando comparada a tratamentos com uma 
Fig. 2 - Survivorship of Leishmania donovani infected-BALB/c mice during treatment with 
diminazene (Dim), artesunate (Art), diminazene plus artesunate (Dim-Art) or amphotericin 
B (Amphot B). BALB/c mice (n = 6) were infected with L. donovani and 10 weeks later, 
treated daily for 28 consecutive days. Data show surviving number of mice per group ± SD 
recorded every week for 14 weeks.
Fig. 1 - In vivo efficacy of diminazene (Dim) alone, Artesunate (Art) alone, combination 
therapy of diminazene/artesunate (Dim-Art) and amphotericin B (Amphot B) in BALB/c 
mice infectecd with Leishmania donovani. The drugs were given at dosages of 12.5 mg/kg 
for 28 consecutive days following nine weeks of disease. At the time of death of mice during 
treatment or at the time of termination at week 14, splenic parasite loads were determined 
and compared for all the groups. Data shown represents the mean ± SD for each group.
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única droga dada nas mesmas dosagens. Embora a carga parasitária tenha 
sido levemente mais baixa (p < 0.05) no grupo Anfotericina B quando 
comparada com o grupo tratado Dim-Art, o estudo presente demonstra 
a vantagem positiva do uso potencial da terapêutica combinada Dim-Art 
sobre drogas como Dim ou Art quando usadas isoladamente. Posterior 
avaliação é recomendada para determinar a média de combinação mais 
eficaz dos dois compostos.
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